SK Biopharmaceuticals is a part of the global conglomerate SK Group, the second largest company in Korea. We're responsible for the development of innovative next-generation drugs within SK Group. SK Biopharmaceuticals has been developing many new drug candidates in the area of CNS, led by the clinical development center(SK Life Science) located in United States and the research center in Pangyo Techno-valley, Gyeonggi-do. With the experience and expertise in the CNS area, SK Biopharmaceuticals will continue to thrive as a successful new drug development company and become a trusted partner through its global R&D network. By 2020, SK Biopharmaceuticals envisions to grow into a global Fully Integrated Pharmaceutical Company (FIPCO) with streamlined capabilities from research to marketing. For more information, visit our website at www.skbp.com.
我们正在追踪 SK Biopharmaceuticals 的市场扩张
最近 90 天内有 2 个信号。
SK Biopharmaceuticals 的国际扩张与竞争对手的对比情况
SK Biopharmaceuticals你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 SK Biopharmaceuticals你 | 0 | 0 | — | 0 | 0 |
RPT Business Development Manager
查看职位Gyeonggi, South Korea · 3周前
Legal Counsel
查看职位Gyeonggi, South Korea · 3周前
경영기획(Corp.Planning Manager)
查看职位Gyeonggi, South Korea · 2个月前
暂无追踪的技术
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
SK生物制药在新泽西州开设「SK Life Science LinX」,为韩国生物科技公司进入美国市场提供160坪设施,包括办公室和会议室。
SK生物制药的癫痫药物Cenobamate和睡眠障碍药物Solriamfetol获得中国NMPA批准，进军中国市场。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 SK Biopharmaceuticals 的业务、市场和增长信号的快速解答。
